Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)

Stopped early · Phase 3

Conditions studied: Constipation-Predominant Irritable Bowel Syndrome

In brief

The main purpose of this study is to evaluate the long-term safety and tolerability of renzapride at a dose of 4 mg taken once daily for 12 months in women with constipation-predominant irritable bowel syndrome (IBS-C).

Key facts

Study ID
NCT00607971
Run by
Alizyme
People needed
939
Starts
2006-04-01
Expected to finish
2008-06-01
Last updated by the study team
2008-07-08

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.